Who are the top shareholders of the Niva Bupa Health?

The top shareholders of Niva Bupa Health are Bupa Singapore Holdings Pte Ltd with 55.98%, followed by foreign institutional investors at 8.9%, mutual funds at 2.68%, and individual investors at 4.23%. There are no pledged promoter holdings, reflecting strong promoter commitment.

The top shareholders of Niva Bupa Health include Bupa Singapore Holdings Pte Ltd, which holds a significant 55.98% of the company. The majority of the remaining shares are held by mutual funds, which account for 2.68% across 14 schemes, and foreign institutional investors (FIIs), who hold 8.9% through 42 different entities. Additionally, individual investors collectively own 4.23% of the shares. Notably, there are no pledged promoter holdings, indicating a strong commitment from the promoters.

Has Niva Bupa Health declared dividend?

No Dividend History Available

Who are the peers of the Niva Bupa Health?

Niva Bupa Health's peers include SBI Life Insurance, HDFC Life Insurance, ICICI Prudential Life, ICICI Lombard, Max Financial, and others. It has excellent growth, average management risk, and lacks a 1-year return for comparison, while HDFC Life Insurance leads with a 37.78% return.

Peers: The peers of Niva Bupa Health are Life Insurance, SBI Life Insuran, HDFC Life Insur., ICICI Pru Life, ICICI Lombard, General Insuranc, Max Financial, Go Digit General, New India Assura, and Medi Assist Ser.<BR><BR>Quality Snapshot: Excellent management risk is observed at ICICI Lombard and Medi Assist Ser., while Average management risk is found at Life Insurance, SBI Life Insuran, HDFC Life Insur., ICICI Pru Life, General Insuranc, Max Financial, Go Digit General, and Niva Bupa Health, and Below Average management risk is noted at New India Assura. Growth is Excellent at Niva Bupa Health and Go Digit General, Average growth is seen at SBI Life Insuran, HDFC Life Insur., ICICI Pru Life, ICICI Lombard, General Insuranc, Max Financial, and the rest, while Below Average growth is present at Life Insurance and New India Assura. Capital Structure is Excellent across all peers.<BR><BR>Return Snapshot: The peer with the highest 1-year return is HDFC Life Insur. at 37.78%, while the peer with the lowest 1-year return is New India Assura at -22.35%. Niva Bupa Health does not have a 1-year return available for comparison. Additionally, the peers with negative six-month returns are General Insuranc, New India Assura, and Medi Assist Ser.

Is Niva Bupa Health overvalued or undervalued?

As of November 27, 2024, Niva Bupa Health is considered very expensive and overvalued, with a PE ratio of 71.14 and significant underperformance at -0.62% year-to-date compared to the Sensex's 5.54%.

As of 27 November 2024, the valuation grade for Niva Bupa Health has moved from does not qualify to very expensive. The company is currently considered overvalued, with a PE ratio of 71.14, an EV to EBITDA ratio of 263.82, and a Price to Book Value of 7.37. These metrics significantly exceed those of its peers, such as Life Insurance with a PE ratio of 12.54 and Bajaj Finance Ltd. at 35.01, indicating a stark contrast in valuation.<BR><BR>In comparison to the broader market, Niva Bupa Health has underperformed, with a year-to-date return of -0.62% against the Sensex's 5.54%. This underperformance, coupled with its high valuation ratios, reinforces the conclusion that the company is overvalued in the current market environment.

What does Niva Bupa Health do?

Niva Bupa Health Insurance Company Ltd, originally Max Bupa, is a mid-cap health insurance provider in India, reporting net sales of ₹15,274 Cr and a net profit of ₹2,061 Cr for Q1 2025. Key metrics include a P/E ratio of 78.00 and a market cap of ₹16,532 Cr.

Overview:<BR>Niva Bupa Health Insurance Company Ltd operates in the insurance industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was originally incorporated as Max Bupa Health Insurance Limited in 2008. It received its Certificate for Commencement of Business on December 23, 2008. The latest quarterly results reported are for March 2025, showcasing the company's performance in terms of sales and profit.<BR><BR>Financial Snapshot:<BR>- Net Sales: 15,274 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 2,061 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 16,532 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 78.00<BR>- Industry P/E: 23<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.12<BR>- Return on Equity: 10.36%<BR>- Price to Book: 7.95<BR><BR>Contact Details:<BR>No Company Details Available. Registrar Address: Not available.

How big is Niva Bupa Health?

As of 24th July, Niva Bupa Health Insurance Company Ltd has a market capitalization of 15,954.00 Cr, with recent net sales of 4,894.46 Cr and a net profit of 213.52 Cr. The company reported shareholder's funds of 2,982.58 Cr and total assets of 6,191.87 Cr for the latest annual period ending March 2024.

As of 24th July, Niva Bupa Health Insurance Company Ltd has a market capitalization of 15,954.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Niva Bupa reported Net Sales of 4,894.46 Cr and a Net Profit of 213.52 Cr.<BR><BR>For the latest annual period ending March 2024, the company had Shareholder's Funds of 2,982.58 Cr and Total Assets amounting to 6,191.87 Cr.

When is the next results date for Niva Bupa Health?

The next results date for Niva Bupa Health is November 3, 2025.

The next results date for Niva Bupa Health is scheduled for November 3, 2025.

How has been the historical performance of Niva Bupa Health?

Niva Bupa Health experienced significant growth from March 2024 to March 2025, with net sales rising to 4,894.46 Cr and profit after tax increasing to 213.52 Cr, while total assets grew to 9,760.16 Cr. The company improved its operating profit margin to 1.19% and enhanced cash flow from operating activities to 1,654.00 Cr.

Answer:<BR>The historical performance of Niva Bupa Health shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Niva Bupa Health's net sales increased from 3,811.25 Cr in March 2024 to 4,894.46 Cr in March 2025, while other operating income rose from 304.22 Cr to 479.82 Cr, leading to a total operating income of 5,374.28 Cr, up from 4,115.47 Cr. Total expenditure, excluding depreciation, also increased to 5,316.18 Cr from 4,254.40 Cr, with employee costs rising slightly and manufacturing expenses significantly increasing from 3,000.37 Cr to 4,061.10 Cr. The company turned around its operating profit, achieving 213.52 Cr in March 2025 compared to 81.85 Cr in March 2024, with a notable improvement in operating profit margin from -3.65% to 1.19%. Profit after tax also saw a substantial increase from 81.85 Cr to 213.52 Cr, resulting in a PAT margin growth from 2.15% to 4.36%. On the balance sheet, total assets grew from 6,191.86 Cr to 9,760.16 Cr, driven by an increase in non-current investments from 5,458.23 Cr to 8,175.08 Cr. Shareholder's funds rose significantly from 2,982.62 Cr to 3,776.22 Cr, while total liabilities increased to 9,760.16 Cr from 6,191.86 Cr. Cash flow from operating activities improved to 1,654.00 Cr from 812.00 Cr, although cash flow from investing activities worsened to -2,347.00 Cr from -1,881.00 Cr. The closing cash and cash equivalents increased to 220.00 Cr from 142.00 Cr, reflecting a positive cash flow trend.

Are Niva Bupa Health latest results good or bad?

Niva Bupa Health's latest results are unfavorable, showing a net loss of ₹35.27 crores in Q2 FY26, a significant decline from a profit last year, despite a 17.21% growth in premium income. The company's negative operating margin and increased losses raise concerns about its profitability and cost management.

Niva Bupa Health's latest results indicate a challenging financial situation. In Q2 FY26, the company reported a net loss of ₹35.27 crores, which is a significant decline compared to a profit of ₹13.02 crores in the same quarter last year. This represents a staggering year-on-year deterioration of 370.89%. <BR><BR>While premium income grew by 17.21% year-on-year to ₹1,422.05 crores, the company's operating margin remains negative at -3.74%, although this is an improvement from -5.40% a year ago. The operating loss before other income widened to ₹53.21 crores, highlighting ongoing struggles with profitability.<BR><BR>Over the first half of FY26, Niva Bupa's combined net sales increased by 18.43% compared to the previous year, yet the total net loss for this period ballooned to ₹126.71 crores, up from just ₹5.80 crores in the same timeframe last year. This sharp increase in losses raises concerns about the company's underwriting practices and cost management.<BR><BR>Overall, while Niva Bupa is experiencing growth in premium income, the substantial losses and negative operating margins suggest that the company's financial performance is currently unfavorable. Investors should approach with caution, as the company needs to demonstrate a path to profitability to regain confidence.

Should I buy, sell or hold Niva Bupa Health?

Is Niva Bupa Health technically bullish or bearish?

As of November 28, 2025, Niva Bupa Health's technical stance is bearish due to negative indicators like a bearish MACD and moving averages, despite a mildly bullish signal from Dow Theory.

As of 28 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Niva Bupa Health is bearish, with a moderate strength. Key indicators driving this stance include the bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands and moving averages on the daily timeframe, and a bearish KST on the weekly. Although the Dow Theory indicates a mildly bullish signal on the weekly, it is outweighed by the overall bearish indicators. The stock has underperformed against the Sensex year-to-date and over the past year, further supporting the bearish outlook.

Which are the latest news on Niva Bupa Health?

Why is Niva Bupa Health falling/rising?

As of 03-Dec, Niva Bupa Health Insurance Company's stock price is declining at 74.70, influenced by poor financial performance, significant drops in profitability, and high valuation concerns. Despite some long-term growth indicators, the stock has underperformed against the benchmark Sensex, leading to cautious investor sentiment.

As of 03-Dec, Niva Bupa Health Insurance Company Ltd's stock price is experiencing a slight decline, currently at 74.70, reflecting a change of -0.01 (-0.01%). This decrease can be attributed to several factors highlighted in the performance metrics and financial results.<BR><BR>In the short term, the stock has underperformed compared to the benchmark Sensex, with a 1-week return of -1.18% against the Sensex's -0.59%. Over the year, the stock has generated a return of -8.95%, significantly lagging behind the Sensex, which has risen by 5.27% during the same period. This consistent underperformance over the last three years indicates a trend that may be discouraging to investors.<BR><BR>Additionally, the company's recent financial results have shown concerning trends. The profit after tax (PAT) for the nine months ending September has decreased by 47.53%, and the profit before tax (PBT) has fallen dramatically by 411.1% compared to the previous four-quarter average. Such declines in profitability can lead to negative investor sentiment and contribute to the stock's falling price.<BR><BR>Moreover, while the stock has shown strong long-term fundamental strength with a 160.87% compound annual growth rate (CAGR) in operating profits and a healthy growth rate in net sales, the current valuation appears expensive with a price-to-book value of 3.6 and a return on equity (ROE) of only 2.4. This high valuation, coupled with flat results, may lead investors to reassess their positions, further contributing to the stock's decline.<BR><BR>Despite a rise in investor participation, as evidenced by a 124.14% increase in delivery volume, the overall sentiment remains cautious due to the company's financial performance and valuation concerns. Thus, these factors collectively explain why Niva Bupa Health's stock price is currently falling.